SeD Biomedical Inc. and Amarantus BioScience Holdings Inc. have entered into a non-binding Letter of Intent for Amarantus to acquire as many as four of SeD Biomedical's biotechnology platforms. Four SeD Biomedical Inc. appointees to the Amarantus board of directors. Rongguo (Ronald) Wei, CPA, CFO at SeD Development Management, LLC as Interim-CFO of Amarantus and Board of Directors, Steven Spence, Managing Director at Dominick & Dickerman as Board of Directors, Robert Trapp, GM at SeD Development LLC Management as Board of Directors and Conn Flanigan, General Counsel at Global Medical REIT at Board of Directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | 0.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 630 | |
+46.03% | 55.66B | |
-7.53% | 38.98B | |
+35.99% | 38.8B | |
-9.38% | 27.32B | |
+12.31% | 26.29B | |
-16.38% | 20.25B | |
+30.79% | 12.76B | |
+28.57% | 12.18B | |
-0.36% | 12.12B |
- Stock Market
- Equities
- AMBS Stock
- News Amarantus BioScience Holdings, Inc.
- Amarantus BioScience Holdings, Inc. Names Four New Appointees to Board of Directors and Interim-CFO